Literature DB >> 27939052

Acoustic Behavior of a Reactivated, Commercially Available Ultrasound Contrast Agent.

Songita A Choudhury1, Feng Xie2, Paul A Dayton3, Thomas R Porter4.   

Abstract

BACKGROUND: Commercially available microbubbles such as Definity contain octafluoropropane encapsulated in a lipid shell. This perfluorocarbon can be compressed into liquid nanodroplets at room temperatures and activated with transthoracic diagnostic ultrasound. The aim of this study was to determine the size range and acoustic characteristics of Definity nanodroplets (DNDs) compared with Definity microbubbles (DMBs).
METHODS: An in vitro flow system was used with a diagnostic ultrasound transducer (S5-1, iE33). DMBs were prepared using package insert instructions. DNDs were prepared by cooling DMBs in a -10°C to -15°C isopropyl alcohol bath before hand-pressurizing the solution. The formed DNDs were sized, diluted to 1% solutions, and infused continuously into a phosphate-buffered saline solution running within Silastic tubing. Acoustic intensity (AI) was compared with equivalent dilutions of DMBs at different mechanical indices (MIs) ranging from 0.2 to 1.4 (n = 6 comparisons at each MI) using real-time 56-Hz and triggered 2-Hz frame rates (FRs). A 3-cm-thick tissue-mimicking phantom was used to simulate transthoracic attenuation. In vivo transthoracic studies were performed in four normal pigs infused with 10% intravenous infusions of DMBs or DNDs at real-time and triggered end-systolic FRs to compare differences in myocardial and left ventricular cavity AI.
RESULTS: DNDs were smaller than DMBs and ranged in size from 50 to 1,000 nm. In vitro studies revealed that at an MI of 0.2 and an FR of 56 Hz, DMBs had high AI (37 ± 2 dB), but AI dropped to 25 ± 2 dB at an MI of 1.0 (P < .001, analysis of variance). In comparison, DNDs had virtually no AI at MIs of 0.2 to 0.6 at both triggered and 56-Hz FRs (1 ± 0 dB), but AI increased to 34 ± 2 dB at an MI of 1.4 using an FR of 56 Hz (P < .001 vs MI of 0.2). AI also persisted longer at 56 Hz with DNDs when using higher MIs. In vivo studies demonstrated higher myocardial AI for DNDs at higher MIs when using real-time FR, most likely from microvascular nanodroplet activation.
CONCLUSION: These data indicate significant differences in acoustic responses of the commercially available DMBs when administered as an equivalent number of DNDs. The DND formulation may render them more useful for high-MI real-time imaging and other targeted transthoracic diagnostic applications.
Copyright © 2016 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acoustic activation; Droplets; Microbubbles

Mesh:

Substances:

Year:  2016        PMID: 27939052     DOI: 10.1016/j.echo.2016.10.015

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  9 in total

1.  Impact of hydrostatic pressure on phase-change contrast agent activation by pulsed ultrasound.

Authors:  Saurabh Raut; Mawia Khairalseed; Arvin Honari; Shashank R Sirsi; Kenneth Hoyt
Journal:  J Acoust Soc Am       Date:  2019-06       Impact factor: 1.840

2.  Novel method for the formation of monodisperse superheated perfluorocarbon nanodroplets as activatable ultrasound contrast agents.

Authors:  C de Gracia Lux; A M Vezeridis; J Lux; A M Armstrong; S R Sirsi; K Hoyt; R F Mattrey
Journal:  RSC Adv       Date:  2017-10-16       Impact factor: 3.361

Review 3.  Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials.

Authors:  Soufiane El Kadi; Thomas R Porter; Niels J W Verouden; Albert C van Rossum; Otto Kamp
Journal:  JACC Cardiovasc Imaging       Date:  2021-10-13

4.  Acoustic Detection of Retained Perfluoropropane Droplets Within the Developing Myocardial Infarct Zone.

Authors:  Ping Zeng; Cheng Chen; John Lof; Elizabeth Stolze; Shouqiang Li; Xucai Chen; John Pacella; Flordeliza S Villanueva; Terry Matsunaga; E Carr Everbach; Hongwen Fei; Feng Xie; Thomas Porter
Journal:  Ultrasound Med Biol       Date:  2022-08-30       Impact factor: 3.694

5.  Selective Enhancement of Swine Myocardium with a Novel Ultrasound Enhancing Agent During Transthoracic Echocardiography.

Authors:  Michael Cimorelli; Michael A Flynn; Brett Angel; Emily Reimold; Sahil S Banka; Benjamin Andrien; Aaron Fafarman; Richard Huneke; Andrew Kohut; Steven Wrenn
Journal:  J Cardiovasc Transl Res       Date:  2022-01-31       Impact factor: 3.216

6.  Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents.

Authors:  David G Ramirez; Mark Ciccaglione; Awaneesh K Upadhyay; Vinh T Pham; Mark A Borden; Richard K P Benninger
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

7.  Delayed Echo Enhancement Imaging to Quantify Myocardial Infarct Size.

Authors:  Ping Zeng; Lijun Qian; John Lof; Elizabeth Stolze; Soufiane El Kadi; Thomas Bargar; Jiri Sklenar; Terry Matsunaga; Feng Xie; Thomas R Porter
Journal:  J Am Soc Echocardiogr       Date:  2021-03-09       Impact factor: 7.722

Review 8.  From Micro- to Nano-Multifunctional Theranostic Platform: Effective Ultrasound Imaging Is Not Just a Matter of Scale.

Authors:  Sara Zullino; Monica Argenziano; Ilaria Stura; Caterina Guiot; Roberta Cavalli
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

9.  Selective infarct zone imaging with intravenous acoustically activated droplets.

Authors:  Songita A Choudhury; Feng Xie; Shelby Kutty; John Lof; Elizabeth Stolze; Thomas R Porter
Journal:  PLoS One       Date:  2018-12-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.